Dyskinesia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
Condition:   Medication-Induced Dyskinesia Interventions:   Drug: NLX-112;   Drug: Placebo Sponsors:   Neurolixis SAS;   Michael J. Fox Foundation for Parkinson's Research;   Parkinson´s UK;   CTC Clinical Trial Consultants AB Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2021 Category: Research Source Type: clinical trials